08:00 , Jan 7, 2008 |  BC Week In Review  |  Clinical News

ACAM-FLU-A: Phase I data

In a double-blind, placebo-controlled, U.S. Phase I trial in adult volunteers, ACAM-FLU-A was well tolerated and immunogenic when given alone or with aluminum hydroxide or QS-21 Stimulon adjuvant. In the latter group, 90% of volunteers...
08:00 , Jan 7, 2008 |  BC Week In Review  |  Clinical News

Acambis preclinical data

In ferrets exposed to the H5N1 virus, 70% of those that received ACAM-FLU-A survived while all animals that received placebo died. ACAM-FLU-A is an influenza A vaccine combining the M2e peptide with a hepatitis B...
08:00 , Jan 7, 2008 |  BC Week In Review  |  Company News

Acambis, Antigenics deal

Acambis exercised an option to receive a non-exclusive license to use Antigenics' QS-21 Stimulon vaccine adjuvant in combination with Acambis' ACAM-FLU-A vaccine. Antigenics is eligible for undisclosed milestones and royalties. The influenza A...
07:00 , Jul 23, 2007 |  BC Week In Review  |  Clinical News

ACAM-FLU-A: Phase I started

ACM started a double-blind, placebo-controlled, U.S. Phase I trial in 80 healthy volunteers to evaluate ACAM-FLU-A alone and in conjunction with an aluminum hydroxide or QS-21 Stimulon adjuvant. ACM has a license to use QS-21...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Clinical News

ACAM-FLU-A: Phase I start

Next quarter, ACM will start a U.S. Phase I trial of ACAM-FLU-A in 60 healthy volunteers. Acambis plc (LSE:ACM), Cambridge, U.K.   Product: ACAM-FLU-A   Business: Infectious   Molecular target: Not applicable   Description: Influenza A vaccine   Indication:...